Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Reborna Biosciences
Fujisawa, Kanagawa, Japan
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
Reborna Biosciences has developed proprietary drug discovery technology enabling small molecule drugs to efficiently and selectively target RNA, opening new avenues for the treatment of rare genetic diseases. Its lead programs—including those for spinal muscular atrophy—are in preclinical development. The company has secured major pharma partnerships, validating the platform but clinical data is not yet available.
- Therapeutic areas
- OncologyNeurologyMetabolic DisordersRare Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
BiogenKissei PharmaceuticalOno Pharmaceutical
Beyond the preview
Go deeper on Reborna Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reborna Biosciences.